US4828836A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release pharmaceutical composition
Assignee: Purdue Pharma LP
•
Filing: 1987-05-19
•
Granted: 1989-05-09
•
Expires: 2007-05-19
Abstract
Abstract A solid, controlled release, pharmaceutical composition comprising an active ingredient incorporated in a controlled release matrix comprising a water soluble polydextrose. The controlled release matrix may also contain at least one of a digestibele C8-C50 substituted or unsubstituted hydrocarbon, especially a C12-C36fatty alcohol, and a polyalkylene glycol, especially polyethylene glycol. Optionally, the matrix may contain a cellulose ether, especially a hydroxyalkylcellulose or a carboxyalkylcellulose.
Inventors
- 👤 Gordon A. Elger
- 👤 Stewart T. Leslie
- 👤 Sandra T. A. Malkowska
- 👤 Ronald B. Miller
- 👤 Philip J. Neale
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 15:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2013; A61K9/2031
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
37 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient incorporated in a controlled release matrix comprising a water soluble polydextrose, said composition containing between about 48% and 90% by weight of the active ingredient.
Claim 2
Dependent Claim
37 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient incorporated in a controlled release matrix comprising a water soluble polydextrose, said composition containing between about 48% and 90% by weight of the active ingredient.
Claim 3
Dependent Claim
17 words
A composition according to claim 1 wherein the active ingredient is selected from theophylline, metocloclopramide and naproxen.
Claim 4
Dependent Claim
42 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient selected from theophylline and naproxen incorporated in a controlled release matrix comprising a water soluble polydextrose, said composition containing between about 48% and 90% by weight of the active ingredient.
Claim 5
Dependent Claim
42 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient selected from theophylline and naproxen incorporated in a controlled release matrix comprising a water soluble polydextrose, said composition containing between about 48% and 90% by weight of the active ingredient.
Claim 6
Dependent Claim
43 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient incorporated in a controlled release matrix which comprises a water soluble polydextrose and at least one of a digestable C 8 -C 50 substituted or unsubstituted hydrocarbon and a polyalkylene glycol.
Claim 7
Dependent Claim
43 words
A solid, oral, controlled release pharmaceutical composition, comprising a solid active ingredient incorporated in a controlled release matrix which comprises a water soluble polydextrose and at least one of a digestable C 8 -C 50 substituted or unsubstituted hydrocarbon and a polyalkylene glycol.
Claim 8
Dependent Claim
17 words
A composition according to claim 4 wherein the hydrocarbon comprises a C 12 -C 36 fatty alcohol.
Claim 9
Dependent Claim
17 words
A composition according to claim 5 wherein the hydrocarbon comprises a C 14 -C 22 fatty alcohol.
Claim 10
Dependent Claim
24 words
A composition according to claim 6 wherein the hydrocarbon comprises a fatty alcohol selected from cetyl alcohol, stearyl alcohol, cetostearyl alcohol and myristyl alcohol.
Claim 11
Dependent Claim
13 words
A composition according to claim 4 wherein the polyalkylene glycol comprises polyethylene glycol.
Claim 12
Dependent Claim
14 words
A composition according to claim 4 wherein the matrix further comprises a cellulose ether.
Claim 13
Dependent Claim
20 words
A composition according to claim 9 wherein the cellulose ether comprises at least one of a hydroxyalkylcellulose and a carboxyalkylcellulose.
Claim 14
Dependent Claim
27 words
A composition according to claim 4 wherein the ratio of polydextrose/cellulose ether to hydrocarbon/polyalkylene glycol in the composition is between 6 to 1 and 1 to 6.
Claim 15
Dependent Claim
18 words
A composition according to claim 11 wherein the ratio is between 4 to 1 and 1 to 4.
Claim 16
Dependent Claim
17 words
A composition according to claim 4 wherein the composition contains between 1% and 80% (w/w) of polydextrose.
Claim 17
Dependent Claim
17 words
A composition according to claim 13 wherein the composition contains between 1% and 50% (w/w) of polydextrose.
Claim 18
Dependent Claim
17 words
A composition according to claim 14 wherein the composition contains between 2% and 40% (w/w) of polydextrose.
Claim 19
Dependent Claim
42 words
A preparation for use in the production of a solid, oral controlled release, pharmaceutical composition comprising a matrix of a water soluble polydextrose and at least one of a digestible C 8 -C 50 substituted or unsubstituted hydrocarbon and a polyalkylene glycol.
Claim 20
Dependent Claim
42 words
A preparation for use in the production of a solid, oral controlled release, pharmaceutical composition comprising a matrix of a water soluble polydextrose and at least one of a digestible C 8 -C 50 substituted or unsubstituted hydrocarbon and a polyalkylene glycol.
Claim 21
Dependent Claim
17 words
A preparation according to claim 16 wherein the hydrocarbon comprises a C 12 -C 36 fatty alcohol.
Claim 22
Dependent Claim
17 words
A preparation according to claim 17 wherein the hydrocarbon comprises a C 14 -C 22 fatty alcohol.
Claim 23
Dependent Claim
24 words
A preparation according to claim 18 wherein the hydrocarbon comprises a fatty alcohol selected from cetyl alcohol, stearyl alcohol, cetostearyl alcohol and myristyl alcohol.
Claim 24
Dependent Claim
13 words
A preparation according to claim 16 wherein the polyalkylene glycol comprises polyethylene glycol.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-05-08 | 1992-11-07 | 1993-05-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-05-08 | 1996-11-07 | 1997-05-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-05-08 | 2000-11-07 | 2001-05-09 | $7700.00 | Window Closed / Lapsed |